Investigation of anti-inflammatory potential of 5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxodihydropyrimidine-4,6 (1H,5H)-dione compound

Página do item simplificado
dc.creatorAlmeida, Dionys de Souza
dc.creatorSilva, Daiany Priscilla Bueno da
dc.creatorMoreira, Lorrane Kelle da Silva
dc.creatorMenegatti, Ricardo
dc.creatorLiao, Luciano Morais
dc.creatorSanz, Germán
dc.creatorVaz, Boniek Gontijo
dc.creatorGhedini, Paulo César
dc.creatorCosta, Elson Alves
dc.creatorFlorentino, Iziara Ferreira
dc.date.accessioned2023-06-27T13:49:03Z
dc.date.available2023-06-27T13:49:03Z
dc.date.issued2020
dc.description.abstractThe aim of this study was to synthesise the novel di-tert-butylphenol compound, 5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-dihydropyrimidine-4,6(1H, 5H)-dione (LQFM218), and evaluate the potential antinociceptive and anti-inflammatory activities in acute (mice) models in vivo. The compound was tested on acute models of pain such as acetic acid-induced abdominal writhing, formalin-induced nociception and carrageenan-induced mechanical hyperalgesia. The anti-inflammatory activity was observed in paw oedema, carrageenan-induced pleurisy tests and inflammatory mediator quantification. Key findings: oral treatment with the LQFM218 (50, 100 or 200 mg/kg) reduced abdominal writhing (18.8%, 31.6% and 48.3%). The dose intermediate (100 mg/kg) reduced the nociception in the second phase of the formalin test (61.4%), and also showed anti-hyperalgic activity in carrageenan-induced mechanical hyperalgesia (until 42.3%). In acute inflammation models, the treatment of mice LQFM218 (100 mg/kg) reduced the paw oedema all the time (33.8%, 42.6%, 37.4% and 36%) and in pleurisy test reduced: polymorphonuclear cell migration (35.4%), myeloperoxidase activity (52.2%) and the levels of inflammatory mediators such as PGE2 (23.0%), TNF-α (67.6%) and IL-1β (53.4%). The present study showed that LQFM218 effectively reduced the nociception and inflammation in different models, and its mechanism might be related to the reduction of PGE2 and proinflammatory cytokines. These findings show LQFM218 as a potential anti-inflammatory drug.pt_BR
dc.identifier.citationALMEIDA, Dionys de S. et al. Investigation of anti-inflammatory potential of 5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione compound. European Journal of Pharmacology, Amsterdam, v. 886, e173388, 2020. DOI: 10.1016/j.ejphar.2020.173388. Disponível em: https://www.sciencedirect.com/science/article/pii/S0014299920304805?via%3Dihub. Acesso em: 21 jun. 2023.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.ejphar.2020.173388
dc.identifier.issne- 1879-0712
dc.identifier.issn0014-2999
dc.identifier.urihttp://repositorio.bc.ufg.br/handle/ri/22773
dc.language.isoengpt_BR
dc.publisher.countryHolandapt_BR
dc.publisher.departmentInstituto de Química - IQ (RMG)pt_BR
dc.rightsAcesso Abertopt_BR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectOedemapt_BR
dc.subjectInflammationpt_BR
dc.subjectNon-steroidal anti-inflammatory drugspt_BR
dc.subjectPainpt_BR
dc.titleInvestigation of anti-inflammatory potential of 5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxodihydropyrimidine-4,6 (1H,5H)-dione compoundpt_BR
dc.typeArtigopt_BR

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Artigo - Dionys de Souza Almeida - 2020.pdf
Tamanho:
1.31 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IQ - Artigos publicados em periódicos